Companies

Johnson & Johnson — due for a shake?

Johnson & Johnson is hunting for potential acquisitions as it seeks to spend $18bn of cash. Perhaps healthcare activists should turn their guns to Switzerland, says Lex’s Rob Armstrong, instead of focusing on the US-based pharma group.